Vivace, a San Francisco Biotech, Raises $40 Million from China-US Investors

Vivace Therapeutics, a Bay-area oncology company, raised a total of $40 million in venture capital from China-US investors. The Series B, which brought in $25 million, was led by new investor Cenova Capital of Shanghai and included Sequoia Capital China and existing investors Canaan Partners, WuXi Healthcare Ventures and Mission Bay Capital. The previously unannounced $15 Million A round was completed in 2015. Sofie Qiao, PhD, president and CEO of Vivace, was head of WuXi Healthcare Ventures before heading up Vivace. Vivace does some of its development work in China, most likely with WuXi AppTech. Until now, Vivace has been in stealth mode. More details.... Share this with colleagues: // //